FDA and FTC Target Delta-8 THC Edibles Resembling Popular Snacks

LOS ANGELES- The Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) are taking action against companies selling delta-8 THC edibles packaged to resemble popular snacks, often marketed towards children. Delta-8 THC is a psychoactive substance found in the Cannabis sativa plant, which includes both cannabis and hemp varieties. The FDA and FTC have expressed concerns about these products’ packaging, which mimics well-known snacks and candies, potentially leading to accidental consumption by children and unsuspecting adults.

The agencies have identified several products, including “Trips Ahoy!” which resembles Chips Ahoy! cookies, and “Slizzies,” similar to Skittles. These look-alike products, including cannabis-infused versions of Flamin’ Hot Cheetos, have caused confusion and pose significant health risks. According to the FTC, companies that sell genuine snack products have no connection to these copycat items, and their trademarks have been misused by marketers.

FTC Bureau of Consumer Protection Director Samuel Levine stated that companies prioritizing profits over children’s safety face serious legal consequences. The FDA reported over 125 adverse event reports related to delta-8 THC edibles from January 2021 to May 2022, with ten specifically mentioning copycat snacks.

The FDA has previously warned about the potential dangers of delta-8 THC products, highlighting that they might expose consumers to higher levels of the substance than naturally found in cannabis extracts. Additionally, the synthesis of delta-8 THC may involve unsafe chemicals, further increasing health risks.

In response to these violations, the FDA and FTC have issued warning letters to companies including Hippy Mood, Earthly Hemps, Shamrockshrooms.com, Mary Janes Bakery Co. LLC, and Life Leaf Medical CBD Center. These companies have been given 15 working days to address these violations and prevent their recurrence. Failure to comply may result in legal action, including product seizures or injunctions.

FDA Principal Deputy Commissioner Namandjé Bumpus emphasized the importance of clear labeling to prevent accidental ingestion, noting the considerable health risks associated with overconsumption of delta-8 THC products. The FDA and FTC will continue monitoring the marketplace to ensure consumer safety and take action against companies selling products that endanger public health.